在心肌缺血/再输后,阿迪波涅丁心脏保护包括减少氧化/化应激
Ling Tao1, Erhe Gao, Xiangying Jiao
1Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Circulation
|March 7, 2007
概括
阿迪波涅丁通过减少氧化应激和炎症来保护心脏免受缺血/反损伤. 这项研究揭示了adiponectin.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 在2型糖尿病患者中,阿迪波涅丁水平降低.
- 阿迪波涅丁水平与心肌缺血风险相反相关.
研究的目的:
- 阐明阿迪波涅克丁对肌肉心脏缺血/再输伤害的保护作用的机制.
主要方法:
- 心肌梗塞大小,细胞亡和氧化应激标志物的比较在接受缺血/再输血的阿迪波涅克丁淘汰和野生型小鼠中.
- 诱导性氧化合成酶 (iNOS) 和gp91的蛋白质表达的评估.
- 评估阿迪波内克球状域管理效应.
主要成果:
- 阿迪波涅丁缺乏症显著增强了心肌亡和心脏病发作的大小.
- 增加氧化物 (NO),超氧化物和过氧化的形成,在阿迪波内克丁缺乏的小鼠中.
- 阿迪波涅克丁的使用可降低缺血/再输血引起的氧化应激,并防止心脏损伤.
结论:
- 阿迪波内克丁是一种天然的心脏保护分子,可以预防缺血/再输液损伤.
- 阿迪波涅丁抑制了iNOS和NADPH-氧化酶,减少了氧化/性压力.
相关概念视频
Anatomy of the Heart
93.4K
The human heart is made up of three layers of tissue that are surrounded by the pericardium, a membrane that protects and confines the heart. The outermost layer, closest to the pericardium, is the epicardium. The pericardial cavity separates the pericardium from the epicardium. Beneath the epicardium is the myocardium, the middle layer, and the endocardium, the innermost layer. There are four chambers of the heart: the right atrium, the right ventricle, the left atrium, and the left ventricle.
93.4K
Ischemic Heart Disease: Overview
3.8K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.8K
Exercise and Cardiovascular Response
6.8K
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
6.8K
Pneumothorax-I
2.2K
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
2.2K
Cardiopulmonary Resuscitation IV: Pharmacological Management
1.7K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.7K
Heart Failure VI: Adjunct Therapies
635
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635


